Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis

Figure 1 PRISMA flow diagram representing breakdown of screened and included studies. PICO: Population, intervention, comparator, and outcome.

Figure 2 Risk of bias assessment of included randomized controlled trials.

Figure 3 Primary efficacy outcomes. A-C: Dose comparison of olezarsen 80 mg vs 50 mg in regard to reduction in triglyceride level (A), non-high-density lipoproteins cholesterol level (B), and apolipoprotein C-III level (C).

Figure 4 Secondary lipid outcomes. A-D: Dose comparison of olezarsen 80 mg vs 50 mg in regard to reduction in low density lipoproteins level (A), very low-density lipoproteins level (B), high-density lipoproteins level (C) and apolipoprotein B level (D).

Figure 5 Overall safety outcomes. A and B: Dose comparison of olezarsen 80 mg vs 50 mg in regard to any adverse events (A) and serious adverse events (B).

Figure 6 Specific safety outcomes. A-D: Dose comparison of olezarsen 80 mg vs 50 mg in regard to hypersenstivity reaction (A), hepatic dysfunction (B), renal dysfunction (C) and thrombocytopenia (D).